Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea

BACKGROUND: In many countries, nephrologists follow clinical practice guidelines for mineral bone disorders to control secondary hyperparathyroidism (SHPT) associated with abnormal serum calcium (Ca) and phosphorus (P) levels in patients undergoing maintenance hemodialysis (MHD). The Kidney Disease Outcomes Quality Initiative (KDOQI) Guidelines have long been used in Korea, and this study was undertaken to investigate the current status of serum Ca and P control in MHD patients. METHODS: Data were collected from a total of 1,018 patients undergoing MHD without intercurrent illness, in 17 hemodialysis centers throughout the country. Serum levels of Ca, P, and intact parathyroid hormone (iPTH) were measured over 1 year, and the average values were retrospectively analyzed. RESULTS: Serum levels of Ca, P, and the CaxP product were 9.1+/-0.7mg/dL, 5.3+/-1.4mg/dL, and 48.0+/-13.6mg2/dL2, respectively. However, the percentages of patients with Ca, P, and Ca x P product levels within the KDOQI guideline ranges were 58.7%, 51.0%, and 70.7%, respectively. Of the 1,018 patients, 270 (26.5%) had iPTH >300pg/mL (uncontrolled SHPT), whereas 435 patients (42.7%) showed iPTH <150pg/mL. Patients with uncontrolled SHPT had significantly higher values of serum Ca, P, and CaxP product than those with iPTH < or =300pg/mL. CONCLUSION: Despite the current clinical practice guidelines, SHPT seems to be inadequately controlled in many MHD patients. Uncontrolled SHPT was associated with higher levels of serum Ca, P, and Ca x P product, suggestive of the importance of SHPT management.

Ectopic ACTH Syndrome and Severe Hypokalemia Associated with Suspicious Pancreatic Malignancy: A Case Report / 대한신장학회지

A 72-year-old woman had a 1-month history of general weakness. Previously, after rectal cancer was treated with a low anterior resection, 12 cycles of adjuvant chemotherapy with 5-fluorouracil plus leucovorin was undergone. Follow-up examination showed no evidence of recurrence. However, she suffered from general weakness attributable to hypokalemia, which was refractory to potassium replacement therapy. After further work-up of the hypokalemia, Cushing's syndrome and ectopic adrenocorticotropic hormone (ACTH) syndrome were diagnosed from the laboratory findings that included a markedly elevated level of 24-hour urine-free cortisol. Several imaging studies revealed masses of the pancreas and other organs, which was more likely to be pancreatic cancer. This case is interesting in that cancerous lesions were identified during work-up of hypokalemia.

High Dose Vitamin D3 Attenuates the Hypocalciuric Effect of Thiazide in Hypercalciuric Rats

Thiazide is known to decrease urinary calcium excretion. We hypothesized that thiazide shows different hypocalciuric effects depending on the stimuli causing hypercalciuria. The hypocalciuric effect of hydrochlorothiazide (HCTZ) and the expression of transient receptor potential vanilloid 5 (TRPV5), calbindin-D(28K), and several sodium transporters were assessed in hypercalciuric rats induced by high calcium diet and vitamin D3. Urine calcium excretion and the expression of transporters were measured from 4 groups of Sprague-Dawley rats; control, HCTZ, high calcium-vitamin D, and high calcium-vitamin D with HCTZ groups. HCTZ decreased urinary calcium excretion by 51.4% in the HCTZ group and only 15% in the high calcium-vitamin D with HCTZ group. TRPV5 protein abundance was not changed by HCTZ in the high calcium-vitamin D with HCTZ group compared to the high calcium-vitamin D group. Protein abundance of NHE3, SGLT1, and NKCC2 decreased in the hypercalciuric rats, and only SGLT1 protein abundance was increased by HCTZ in the hypercalciuric rats. The hypocalciuric effect of HCTZ is attenuated in high calcium and vitamin D-induced hypercalciuric rats. This attenuation seems to have resulted from the lack of HCTZ's effect on protein abundance of TRPV5 in severe hypercalciuric condition induced by high calcium and vitamin D.

A case of chinese herb nephropathy induced by aristolochia fangchi / 대한내과학회지

Chinese herb nephropathy (CHN) is characterized by progressive tubulointerstitial nephritis and development of renal failure in a couple of years after diagnosis. Aristolochic acid (AA) is believed to be associated with the development of CHN. The authors report a case of CHN in which AA in the herb regimen was identified by high-performance liquid chromatography (HPLC). A 32-year-old female presented with nausea, vomiting and generalized weakness. She had been taking Chinese herbs for symptomatic care. Clinical and laboratory examinations revealed Fanconi syndrome, renal failure, and severe anemia. Renal biopsy showed severe tubulointerstitial nephritis with moderate tubular atrophy and interstitial fibrosis. She developed end-stage renal failure 4 months after diagnosis. The herb she had been taking was Aristolochia fangchi. HPLC technique was used to identify AA and to measure its concentration in the herb. From the clinical and laboratory data, the patient was diagnosed with CHN caused by aristolochic acid.

Clinical Features Of Patients With Hyperphosphatemia Following Administration Of Phosphate-Containing Laxatives / 대한내과학회지

BACKGROUND: Oral sodium phosphate (NaP) is currently used for colon preparation prior to colonoscopy or barium enema because of its convenience and efficacy. It can cause transient hyperphosphatemia and should be considered potentially dangerous in the presence of renal impairment. METHODS: A retrospective study was done in 48 patients (32 patients with normal renal function and 16 patients with azotemia : serum creatinine >or= 1.4 mg/dL) with hyperphosphatemia (serum phosphate >or= 6 mg/dL or 50% increase in baseline) who were administered NaP solution as bowel preparation at Seoul National University Hospital in the period of January 2000 to June 2003. RESULTS: The patients' mean age was 60 years (range, 25-85 years). The increase of serum phosphate was 5.3 +/- 3.1 mg/dL (7.6 +/- 4.4 mg/dL in azotemia group vs. 4.2 +/- 1.2 mg/dL in normal renal function group). Serum calcium and potassium concentration decreased significantly, while serum sodium level increased significantly. There were no significant differences in serum chloride, total CO2, blood urea nitrogen and creatinine. The product of calcium and phosphate increased from 33.0 +/- 11.3 mg2/dL2 to 74.0 +/- 28.7 mg2/dL2 (to 93.0 +/- 39.8 mg2/dL2 in azotemia group). Only 8 patients ingested the recommended dose of oral NaP with an appropriate time interval. The symptomatic adverse events were numbness in 3 patients and carpopedal spasm in 1 patient. 12 patients underwent CaCO3 or amphojel administration and 1 patient needed hemodialysis as a treatment of hyperphosphatemia. Serum phosphate returned to baseline level at 1.3 +/- 0.6 day (1.8 +/- 0.8 day in azotemia group vs. 1.0 +/- 0.3 day in normal renal function group). CONCLUSION: NaP is inappropriate for patients who may be at an increased risk for phosphate intoxication, especially patients with impaired renal function. Even to healthy adult without renal disease, NaP should be ingested the recommended dose with an appropriate time interval.